Fig. 4: BCR::ABL1^IS ≤ 1% by time point.^a

ASC asciminib, DAS dasatinib, IMA imatinib, NIL nilotinib. ^aExcludes patients with atypical/p190 (e1a2 or e1a3)/unknown transcripts and those with a missing evaluation at screening.